How should tranexamic acid be used to treat melasma, including dosing, duration, and contraindications?

Tranexamic Acid for Melasma

Oral tranexamic acid at 250 mg twice daily for 12 weeks is the optimal evidence-based treatment for melasma, with significant efficacy demonstrated in reducing MASI scores and an acceptable safety profile when appropriate screening is performed.

Dosing and Administration

Optimal Dosing Regimen

The preferred oral dose is 250 mg twice daily (total 500 mg/day) for 12 weeks 1, 2. Network meta-analysis demonstrates that 750 mg per day for 12 consecutive weeks provides optimal efficacy, but 250 mg twice daily represents the best balance between effectiveness and medication adherence 2. For poorly adherent patients, 250 mg once daily may be acceptable, though it shows slower initial response with comparable efficacy by 16 weeks 3.

Route Comparison

While tranexamic acid can be administered via multiple routes, oral administration combined with routine topical agents (hydroquinone, kojic acid, sunscreen) demonstrates superior efficacy compared to intradermal injection, topical application, or microneedling 4, 5. The evidence from 2025 guidelines shows that intradermal PRP actually outperforms intradermal tranexamic acid (4 mg/mL, maximum 8-16 mg per session) 4, making oral administration the preferred route for tranexamic acid specifically.

Treatment Duration and Maintenance

• Initial treatment: 12 weeks minimum 2, 5
• Onset of effect: Significant improvement begins at 8 weeks 3, 5
• Maintenance: Repeated courses may be required as melasma should be managed as a chronic condition with regular follow-ups 4, 1
• Discontinuation: Can be stopped abruptly without tapering 1

Pre-Treatment Evaluation

Mandatory Screening

Before initiating oral tranexamic acid, obtain:

History:

• Risk factors for thromboembolism (personal or family history of DVT, PE, stroke)
• Cardiovascular disease history
• Menstrual disorders
• Current medications, especially hormonal contraceptives 1

Baseline Laboratory Testing:

• All patients: Coagulation profile (PT/INR, aPTT) 1
• High-risk patients: Complete blood count, liver function tests, protein C and S levels 1

Monitoring During Treatment

• Repeat coagulation profile every 3 months, especially in patients with clinically higher risk of thromboembolism 1
• For treatment >3 months: Consider ophthalmic monitoring including visual acuity and optical coherence tomography at regular intervals 6

Contraindications

Absolute Contraindications

Per FDA labeling, tranexamic acid is contraindicated in 6:

• Active intravascular clotting
• History of thromboembolic events (DVT, PE, cerebral thrombosis, MI)
• Subarachnoid hemorrhage (risk of cerebral edema and infarction)
• Hypersensitivity to tranexamic acid

Relative Contraindications and Cautions

• Avoid concomitant use with prothrombotic medications: Factor IX concentrates, anti-inhibitor coagulant concentrates, and hormonal contraceptives increase thrombosis risk 6
• Renal impairment: Dose reduction required 6
• History of seizures: Monitor closely as tranexamic acid may cause seizures 6

Adverse Effects and Safety

Common Side Effects

• Gastrointestinal: nausea, vomiting, diarrhea (may resolve with dose reduction) 6
• Oligomenorrhea and menstrual irregularities 3
• Abdominal discomfort 3
• Dizziness (advise patients not to drive until they know how it affects them) 6

Serious Adverse Effects (Rare)

• Thromboembolic events: DVT, PE, cerebral thrombosis, acute renal cortical necrosis, retinal artery/vein obstruction 6
• Seizures: Particularly with high doses or inadvertent neuraxial administration 6
• Visual disturbances: Chromatopsia, visual impairment (though no retinal changes observed in humans treated up to 8 years) 6
• Hypersensitivity reactions: Including anaphylaxis 6

Clinical Algorithm

Step 1: Patient Selection

• Confirm melasma diagnosis (dermoscopic evaluation recommended) 4
• Screen for contraindications (thromboembolism history, active clotting disorders)
• Obtain baseline coagulation profile (all patients) and extended workup (high-risk patients)

Step 2: Initiation

• Start oral tranexamic acid 250 mg twice daily
• Combine with topical agents (hydroquinone, kojic acid) and strict sun protection 4, 1
• Counsel patient on chronic nature of condition and need for sun protection

Step 3: Monitoring

• Follow-up at 4-week intervals to assess MASI score reduction 7, 8
• Repeat coagulation profile at 3 months (especially high-risk patients) 1
• If treatment extends beyond 3 months, consider ophthalmologic evaluation 6

Step 4: Duration and Discontinuation

• Continue for minimum 12 weeks 2
• Assess response: expect significant improvement by 8 weeks 3, 5
• Can discontinue abruptly without tapering 1
• Plan for repeated courses if relapse occurs 1

Important Caveats

Relapse is common: Melasma frequently recurs after discontinuation, requiring repeated treatment courses. Patients should understand this is a chronic condition requiring ongoing management 4, 1.

Combination therapy is superior: Oral tranexamic acid works best when combined with topical agents and rigorous sun protection, not as monotherapy 4, 5.

Thrombosis risk is real but rare: While serious thromboembolic events are uncommon, appropriate screening and monitoring are essential, particularly in patients with risk factors or those using hormonal contraceptives 6, 1.

Route matters: If considering injectable tranexamic acid, be aware that PRP demonstrates superior efficacy compared to intradermal tranexamic acid injections 4.